الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
The present study was performed on 70 individuals
categorized as follows:
•Thirty patients suffering from bronchogenic carcinoma, (26 males and 4 females), 19 were smokers and 11 non-smokers with their age ranging from 33 to 80 years (mean of 63).
•Twenty patients with benign chest diseases, 10 patients with
pulmonary tuberculosis, and 10 patients with chronic obstructive pulmonary disease, their sex and age were matched with bronchogenic carcinoma group.
•Twenty apparently healthy individuals as reference group, their sex and age were matched with other groups.
Serum samples were obtained from patients before treatment had been instituted in order to avoid any effect of therapy. Hemolytic sera were excluded to avoid the effect of hemolysis on serum markers.
CYFRA 21-1 levels were measured in the serum by an immunoradiometric assay (IRMA), using two mouse MoAb, KS 19-1 and BM 19-21. Serum CYFRA 21-1 of 1.1 ng/ml was considered the cut off value of CYFRA 21-1.
121
Summary & ComJuan
elevation of serum CYFRA 21-1 and CEA was found in patients with squamous cell carcinoma.
It is apparent from the present study that, patients with advanced disease (stage IV) showed the highest percentage of positivity of both CYFRA 21-1 and CEA.
from the present study, the sensitivity of CYFRA 21-1 in bronchogenic carcinoma (73.3%) was found to be higher than the sensitivity of CEA (53.3%). Also, the specificity of CYFRA 21-1 (71.4%) was higher than the specificity of CEA (58.8%). The sensitivity of the combined measurement of CYFRA 21-1 and CEA (86.7%) was found to be higher than the sensitivity of CYFRA 21-1 alone.
It is apparent from the present study that, there was a significant intermarker correlation between CYFRA 21-1 and CEA.
Also there was a significant positive correlation between CYFRA 21-1 and lung cancer stage and also between CEA and lung cancer stage.